Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Although the 1970s saw a gradual shift from the use of cryoprecipitate, largely in hospitals, by 1975 around 50% of haemophilia centres were using cryoprecipitate for some part of their home therapy programmes.

  • Read more about Although the 1970s saw a gradual shift from the use of cryoprecipitate, largely in hospitals, by 1975 around 50% of haemophilia centres were using cryoprecipitate for some part of their home therapy programmes.

A witness told the Inquiry that such were the effects of his haemophilia before he went to Lord Mayor Treloar's College that: "I think at age six I went to school for three days in the year. And then in the following year, I think I probably went for about nine days."

  • Read more about A witness told the Inquiry that such were the effects of his haemophilia before he went to Lord Mayor Treloar's College that: "I think at age six I went to school for three days in the year. And then in the following year, I think I probably went for about nine days."

In a profile of haemophilia management in Northern Ireland, Dr Mayne described how "In 1967 a milestone occurred; a revolutionary concentrate was produced called 'cryoprecipitate'."

  • Read more about In a profile of haemophilia management in Northern Ireland, Dr Mayne described how "In 1967 a milestone occurred; a revolutionary concentrate was produced called 'cryoprecipitate'."

Even by 1990, after concentrates had become very widely used, Dr Mayne summarised her opinion as being "the selection of mode of treatment depends upon the category or type of patient concerned. In respect that cryoprecipitate and Factor VIII concentrates are both efficacious treatments, preference of the one over the other depends on the age, the severity of the haemophilia and whether the patient is on a self-treatment programme, or requires major or minor surgery."

  • Read more about Even by 1990, after concentrates had become very widely used, Dr Mayne summarised her opinion as being "the selection of mode of treatment depends upon the category or type of patient concerned. In respect that cryoprecipitate and Factor VIII concentrates are both efficacious treatments, preference of the one over the other depends on the age, the severity of the haemophilia and whether the patient is on a self-treatment programme, or requires major or minor surgery."

In her expert witness report regarding the HIV litigation, Dr Mayne described the advantages of cryoprecipitate, amongst which were "efficacy, low donor exposure, simplicity of manufacture" set against some disadvantages; its discovery "transformed Haemophilia treatment".

  • Read more about In her expert witness report regarding the HIV litigation, Dr Mayne described the advantages of cryoprecipitate, amongst which were "efficacy, low donor exposure, simplicity of manufacture" set against some disadvantages; its discovery "transformed Haemophilia treatment".

By 1977 Dr Jones remained of the view that cryoprecipitate had made a significant difference to the advantage of patients - talking of both cryoprecipitate and freeze-dried concentrates in the same breath as having made a difference, but then pointing out that Factor 8 concentrate was not without its problems, principal among which was that it was a significant cause of hepatitis.

  • Read more about By 1977 Dr Jones remained of the view that cryoprecipitate had made a significant difference to the advantage of patients - talking of both cryoprecipitate and freeze-dried concentrates in the same breath as having made a difference, but then pointing out that Factor 8 concentrate was not without its problems, principal among which was that it was a significant cause of hepatitis.

Commercial concentrate was to be used in the management of severe bleeds, not as first choice, but as second best to cryoprecipitate. Dr Jones stated: "When insufficient cryoprecipitate is available."

  • Read more about Commercial concentrate was to be used in the management of severe bleeds, not as first choice, but as second best to cryoprecipitate. Dr Jones stated: "When insufficient cryoprecipitate is available."

The 1970s saw a gradual shift from the use of cryoprecipitate, largely in hospitals.

  • Read more about The 1970s saw a gradual shift from the use of cryoprecipitate, largely in hospitals.

Dr Jones remained of the view that cryoprecipitate had made a significant difference to the advantage of patients.

  • Read more about Dr Jones remained of the view that cryoprecipitate had made a significant difference to the advantage of patients.

Dr Jones attributed the fact that people with haemophilia were expected to live a normal life-span to the identification of Factor 8, the organisation of the blood transfusion services post war - and to cryoprecipitate.

  • Read more about Dr Jones attributed the fact that people with haemophilia were expected to live a normal life-span to the identification of Factor 8, the organisation of the blood transfusion services post war - and to cryoprecipitate.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 451
  • Page 452
  • Page 453
  • Page 454
  • Current page 455
  • Page 456
  • Page 457
  • Page 458
  • Page 459
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.